Hyderabad startup gets CDSCO nod for pain management wearable

Hyderabad-based Litemed’s CURAPOD, India’s first non-invasive pain management wearable, has received CDSCO approval. Using photobiomodulation technology, it provides personalised, drug-free therapy for over 30 conditions. Available across India, the device comes with a companion app and expert consultation

Hyderabad: A Hyderabad-based health-tech startup has received approval from Indian drug regulatory authority Central Drugs Standard Control Organisation (CDSCO), for its Made-in-India, non-invasive pain management wearable device ‘CURAPOD’.

CURAPOD, powered by health-tech company Litemed, is already in use at several health and wellness centres in Hyderabad. It is based on clinically validated photobiomodulation technology that delivers medical grade red and near-infrared light to promote cellular repair, reduce inflammation, and accelerate recovery, the company said in a statement on Monday.

---

Its adaptive engine calibrates therapy intensity in real time based on muscle response, often providing noticeable relief within 30 minutes. “Registered with the CDSCO and the FDA, the CURAPOD stands as India’s first non-invasive personalised pain management device,” Litemed said.

“The wearable device is designed for over 30 conditions, including chronic back and knee pain, arthritis, tendonitis, sports injuries, and everyday strain. It provides 100 per cent drug-free therapy with no side effects and comes with a 1-year warranty along with free expert consultation. Its adaptive system adjusts intensity based on user comfort, offering consistent and targeted pain relief,” says Surya Maguluri, Founder and CTO, CURAPOD, backed by Litemed India Private Limited.

The device comes with a companion mobile app, which personalises therapy plans, tracks progress, and monitors pain, enabling professional-grade treatment at the comfort of home. The data-driven approach allowed clinicians to monitor progress remotely and refine therapy programmes, he said.

Curapod is currently available across India through the company’s D2C website and will be listed on leading marketplaces from the first quarter of 2026, the statement added.